Diabetic retinopathy (DR) is a common microvascular complication of diabetes that affects nearly all the type 1 diabetes patients and >60% of type 2 diabetes patients 1 and is the leading cause of new-onset blindness and vision loss among the working-age population in the developed world, 1 with approximately 24 000 people losing vision from DR each year in the United States alone. Studies have demonstrated that early detection and treatment of DR helps reverse DR signs, and slow DR progression. 2 Therefore, identification of patients in early stages of DR who are at high risk for progression to the sight-threatening stages of DR is crucial to reduce vision loss due to DR. 2 Annual DR screening is the current clinical recommendation 1 for diabetic patients. However, many diabetic patients do not get annual DR screening since DR can progress over several years without symptoms or discomfort before reaching a sight-threatening stage. The CDC reports that in 2010 US eye care practitioners examined less than 63% of the estimated 23 million people with diabetes, leaving millions of people at risk for potentially preventable visual loss and blindness. 3 Most DR screening programs use digital fundus cameras to acquire color images of the retina. Multiple photographs are obtained for each patient encounter (or a visit), and then examined for the presence of pathologies indicative of DR including microaneurysms (MAs), hemorrhages, hard exudates, cotton wool spots, intraretinal microvascular abnormalities (IRMAs), and neovascularization. Manual DR screening is time-consuming and prone to inter-and 628546D STXXX10.1177/1932296816628546Journal of Diabetes Science and TechnologyBhaskaranand et al
intragrader variability. Manual DR screening alone cannot meet the screening needs of the large and growing diabetic population (The worldwide diabetic population is estimated to be 387 million in 2014 and reach 592 million by 2035.) 4 Therefore, automated DR screening methods are essential for screening a large diabetic patient population for DR. Moreover, automated DR screening methods can make the DR screening process more efficient, cost-effective, reproducible, and accessible. 5 The primary goal of DR screening systems is to identify patients who need referral to an eye care specialist for possible treatment due to elevated risks progressing to vision loss and blindness due to DR. The risks for progression are different for the various stages of the disease. 6 The International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales (ICDR) 6 were formulated by a consensus of international experts to capture the DR stages relevant to screening and standardize DR classification. The ICDR scale defines 5 stages of DR-no apparent DR, mild nonproliferative DR (NPDR), moderate NPDR, severe NPDR, and proliferative DR (PDR)-and apparent macular edema (ME) present or absent. The severe NPDR and PDR stages are termed sight-threatening DR due to the high risk of vision loss in these stages. There is clinical evidence that the risk of progression to sight threatening DR over several years in patients with no DR or mild NPDR without ME is very low, and therefore such patients usually need not be immediately referred to an eye care specialist and can be screened again in one or two years. 5 Therefore, a DR screening system that identifies patients with moderate NPDR or ME and recommends referral to an eye care specialist for DR monitoring and/or clinical intervention will help reduce the burden on the scarce resources of eye care specialists.
Although the risk of patients with mild NPDR (characterized by only MAs) progressing to sight threatening DR is usually very low, there is clinical evidence that the rate of appearance and disappearance of MAs, termed as MA turnover, is a better predictor of DR progression risk than the DR level. [7] [8] [9] MAs, which are small swellings that occur in capillaries, are the first clinically evident signs of DR and are dynamic 10 with new MAs being continuously formed while existing ones may disappear. Therefore, MA identification and monitoring is the first step in the clinical process of risk stratification of DR for appropriate patient education and possible treatment of high risk disease.
Despite the clinical utility, MA turnover is not widely used in current clinical practice since manual evaluation of MA turnover is time-consuming requiring two labor-intensive tasks: careful alignment of longitudinal fundus images (ie, fundus images from two different encounters) and identification of the MAs. In addition, the process of identifying and matching MAs suffers from poor reproducibility. 11 Automated analysis can provide fast, robust, and reproducible MA turnover metrics that can be used as a potential biomarker for DR risk monitoring.
In this article, we present and evaluate an automated tool for screening DR patients and its extension for estimating the MA turnover via longitudinal analysis. First we discuss EyeArt v1.2 (Eyenuk, Inc, Los Angeles, CA), a novel and robust automated DR screening system that can analyze variable number of images per patient encounter, identify gradable images ( Figures 1A, 1B ), exclude nonretinal images ( Figures 1C, 1D ) and nongradable images ( Figures 1E, 1F ) from analysis, and provide a recommendation for referral to an eye care specialist for patients whose encounter images show signs of moderate NPDR or higher or surrogate markers for ME on the ICDR scale. The EyeArt tool is implemented as a scalable, high-throughput, cloud-based system to enable analysis of large DR screening data sets. Next we extend the DR screening tool to perform longitudinal analysis across multiple encounters of a patient to estimate MA turnover, a potential biomarker for DR risk that can be used for DR monitoring. This novel MA turnover estimation tool, EyeMark v0.7 (Eyenuk, Inc, Los Angeles, CA), can automatically analyze images from multiple encounters of a patient with each encounter containing multiple images, detect MAs, identify corresponding retinal fields across encounters by registering the images, and then estimate MA turnover. Similar to the screening tool, the MA turnover estimation tool is cloud-based and designed for high scalability and throughput.
On a data set of 5084 diabetic patient encounters from EyePACS, 12 a DR telescreening system, we show that the DR screening tool achieves high screening sensitivity at reasonably high specificity values. With minimal workload of human graders having to review 26% of the encounters, system performance of 90% sensitivity and 90% specificity can be achieved. On a subset of 7 longitudinal pairs, we show that the MA turnover estimation tool identifies new and disappeared MAs with 100% sensitivity and average false positives of 0.43 and 1.6, respectively.
Methods

Data Set
We present the analysis on a diabetic patient encounter screening data set from EyePACS, 12 a DR telescreening system with users in over 360 primary care clinics in the United States and elsewhere. The EyePACS data set included a total of 40 542 color fundus images of 5084 diabetic patient encounters without any patient identifying data. The images were captured using multiple color fundus cameras at different clinics and had resolutions ranging from 1396 × 1396 (2 million pixels) to 3168 × 4752 (15 million pixels). The distribution of the DR and diabetic macular edema (DME) levels in this data set is presented in Table 1 . Each of the 5084 encounters had 1 to 17 images including external eye images.
Of these encounters, 60 were from 25 patients with at least 2 encounters, and these were identified by an anonymized patient id. These deidentified images were captured between April 2006 and December 2013 at various DR screening centers that use the EyePACS Retinal Reading Program.
Based on the presence and severity of the various DR lesions each patient encounter is assigned a DR severity level as per the international clinical diabetic retinopathy (ICDR) scale 6 by a human expert, with 0 for no apparent DR, 1 for mild NPDR, 2 for moderate NPDR, 3 for severe NPDR, and 4 for PDR, and an ME level with 0 for no ME and 1 for ME. A patient was deemed to have nonreferable DR if there was no NPDR or mild NPDR and no ME in both eyes. The "refer" and "no refer" labels from the human experts were used as the reference standard.
Automated DR Screening
The computerized screening tool EyeArt assesses the severity of DR based on multiple color fundus images captured during a patient encounter, and provides a recommendation for referral to an eye care specialist if the patient is deemed to have ME or moderate NPDR or higher on the ICDR scale. The primary output of the tool is a "refer" or "no refer" screening recommendation. The screening tool is designed to provide a "refer" recommendation when it detects signs of moderate NPDR or higher on the ICDR scale, detects signs of ME, or deems the encounter as nongradable. EyeArt outputs a decision statistic that can be used to assess the confidence in the recommendation. In addition, the screening tool provides a "confident refer" recommendation when the decision statistic is above the 98% specificity threshold and a "borderline refer" recommendation when the decision statistic is between the 90% sensitivity and 98% specificity thresholds. The overall block diagram of the EyeArt system is shown in Figure 2 . In the following sections we describe the different blocks.
Image Gradability. The patient encounter comprising multiple color fundus images is first analyzed for gradability. Nonretinal images such as those of the external image of the eye and retinal images that cannot be graded for signs of DR due to Corresponding enhanced images. Images from these different cameras are normalized to images with similar dynamic ranges, making them suitable for further analysis using the same algorithms with identical algorithm parameters. various factors such as poor illumination, over-exposure and poor focus are excluded from further analysis. Generic descriptors including histogram of gradients (HOG), 13 color histograms, sum modified Laplacian focus descriptors, 14 Michelson-contrast descriptors 15 are computed for each image and input to a supervised-learning classifier to produce an image-level gradability output. A patient encounter is deemed as gradable if it has at least one gradable retinal image per eye showing the macula. Nongradable patient encounters are not analyzed and flagged as having insufficient data.
Image Enhancement. Retinal fundus images have different colors levels, different dynamic range, and different sensor noise. Image enhancement is necessary to normalize the appearance and enhance the appearance of lesions (see Figure 3 ). For enhancement, the gradable images are first subjected to an edge-preserving bilateral filter 16 to remove noise without affecting the important landmarks such as lesions and vessels and then subject to median normalization. The median normalized intensity I Norm, at pixel location ( , ) x y is Interest Region Detection. The enhanced images are then analyzed to identify regions of the image potentially containing interesting anatomical or pathological structures. The interest region detector is based on multiscale morphological filterbank analysis that identifies putative lesion-specific interest regions. On average, less than 1% of the pixels are identified as interest regions. For example (see Figure 4 ), on a retinal image with over 5 million pixels, further processing is focused on about 25,000 interesting pixels which is about 0.5% of the pixels in the image.
Descriptor Computation. The pixels identified by the interest region detector are described using a set of feature descriptors (multiscale median filterbank descriptors, oriented median filterbank descriptors, and other established descriptors) that allow local description at multiple scales. The interesting pixels are analyzed using supervised learning classifiers for identifying MAs, hemorrhages, hard exudates, cotton wool spots, IRMAs, and neovascularization.
DR Screening Classification. The pixel-level classifier decision statistics are averaged within each lesion to obtain the lesionlevel decision statistics. The histograms of lesion-level decision statistics for different lesion types are collated to generate the image-level descriptor. The image-level descriptors for all the gradable images in a patient encounter are combined to generate an encounter-level descriptor that is classified using a supervised learning ensemble classifier to detect the presence of moderate NPDR or higher on the ICDR scale.
Automated MA Turnover Estimation for DR Monitoring
The overall block diagram of the EyeMark system for automated computation of MA turnover is shown in Figure 5 . Typically there are multiple images per patient encounter. Fovea centered images for each eye are automatically identified among the multiple images captured during both the baseline and longitudinal encounter and paired. These images are then aligned/registered using vasculature feature based multiscale registration. The aligned images are analyzed for MA using ensemble classification of many local image properties. The obtained MA confidence maps are used to evaluate turnover.
Image Registration. Accurate registration is essential for tracking changes in small lesions such as MAs. Registration involves determining landmark structures that can be consistently identified in both the baseline and longitudinal images.
We use retinal vasculature based landmarks 17 since they can be assumed to be stationary/nonchanging across multiple encounters. Robust registration is achieved using a multiscale approach. Coarse vascular features at the coarsest scale are matched first to get a robust, coarse registration model that is then progressively refined using finer vasculature features at higher scales that are geometrically within an error window ("close enough") as per the registration model computed in the coarser scale.
Ensemble Classification. The registered images are processed for localizing MAs as described in the section on Automated DR screening. The computed pixel descriptors are classified using an ensemble supervised learning classifier to obtain decision statistics describing the confidence of a pixel belonging to a MA. The pixel-level decision statistics are averaged within each "blob" and run through a sigmoid nonlinearity with negative values being clipped to zero, to generate the MA confidence map with confidence values in range [ , ] 0 1 .
Turnover Estimation. The difference confidence map is the computed by subtracting the longitudinal MA confidence map from the baseline MA confidence map. Blob locations in the difference confidence map that have absolute values less than persistent lesion threshold ( ) T p and values higher than baseline lesion threshold ( ) T b in the baseline MA confidence map are marked as persistent MA locations with confidence as per the value in the baseline confidence map. Blob locations in the difference confidence map that are over a new lesion threshold ( ) T n are marked as new MA locations with the difference value as the confidence level. Blob locations in the difference image that are below disappeared lesion threshold ( ) T d are marked as disappeared MAs with the absolute of the difference value as the confidence level. Values of T p = 0 1 . , T b = 0.3, T n = 0 3 . and T d = −0 3 . were empirically found to give the best results. Positive turnover rate is computed as the sum of confidence values of the new MAs divided by the time difference between encounters in years and negative turnover rate is the sum of confidence values of disappeared MAs divided by the time difference between encounters in years. The maps of new, persistent, and disappeared MAs are also output (see Figure 6 ).
Results
All of the 5084 encounters from the EyePACS data set were processed by EyeArt screening tool. EyeArt marks 70 (1.4% of the data set) as nongradable and these encounters are considered to have a "refer" recommendation for this analysis. EyeArt screening sensitivity is 90.0% (95% CI: 88.0%-92.0%) at specificity of 63.2% (95% CI: 61.7%-64.6%) at an operating point of -0.84 on the decision statistic. The receiver operating characteristic (ROC) curve is shown in Figure 7 . The area under the ROC curve (AUROC) is 0.879 (95% CI: 0.865-0.893). There are 87 false negatives (only 1.7% of the encounters) out of which 77 do not meet the treatment criteria, that is, have moderate NPDR and no ME. 6 The sensitivity for detecting encounters with sight-threatening DR is 96.8%, that is, 304 encounters are recommended for referral of the 314 that are marked in the reference standard as having sightthreatening DR.
If the 1304 encounters with "borderline refer" recommendations are reviewed by a human grader then the system achieves 90% sensitivity at 90% specificity with 26% workload. This assumes that "borderline refer" encounters are assigned the same grade as the reference standard grade.
In all, 25 patients were imaged at multiple encounters and the longitudinal images from the patient encounters were analyzed using EyeMark. All the longitudinal pairs were successfully registered and MA turnover analysis was performed. On a subset of 7 longitudinal encounter pairs from the above set, an expert from Doheny Eye Institute marked the new, persistent, and disappeared MAs. As listed in Table 2 , EyeMark has high sensitivity for new and disappeared MAs. Persistent MAs do not have any bearing for turnover estimation.
Discussion
We have presented a DR screening approach and have extended it to develop an image-based biomarker for DR. Together these tools can potentially be useful in automation of critical and time consuming aspects of DR screening and monitoring.
The EyePACS data set that we have analyzed in this article was chosen from an actual DR screening setup to demonstrate utility in actual clinical practice. On this data set, the automated screening tool has high sensitivity at good specificity values for identifying encounters with moderate NPDR or higher or with DME. With minimal workload of human graders having to review 26% of the encounters, system performance of 90% sensitivity and 90% specificity can be achieved in a telemedicine DR screening setup.
Generally, mild NPDR encounters are not referred to the eye care specialist. With the biomarker from the MA turnover estimation tool, mild NPDR encounters with high turnover rates can be flagged and scheduled for DR screening more frequently than the annual screening which would be commonly recommended. The noninvasive biomarker can be a valuable tool for clinicians and retina specialists to monitor DR progress and educate patients. Thus with DR monitoring, the progress of DR can be significantly slowed and risk of vision loss can be substantially reduced.
Conclusions
The DR screening tool achieves high sensitivity of 90% at reasonable specificity of 63.2% on a data set of 40 542 color retinal images from 5084 patient encounters obtained from the EyePACS telemedicine screening systems. With humans grading only the "borderline refer" encounters the screening tool provides a workload reduction of 74% (with 90% sensitivity and 90% specificity) on this data set. The MA turnover estimation tool achieves high sensitivity for new and disappeared MAs and can be reliably used to compute MA turnover rates.
The use of automated DR screening and monitoring tools as presented in this article can greatly reduce the burden on health care systems while providing improved care to the diabetic population.
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